Evidence map›Paper›PMID 38817898›Full record

ArticleFrontiers in oncology2024

Multiplicity of benign breast disease lesions and breast cancer risk in African American women.

Vidya Patil, Julie J Ruterbusch, Wei Chen, Julie L Boerner, Eman Abdulfatah, Baraa Alosh, Visakha Pardeshi, Asra N Shaik, Sudeshna Bandyopadhyay, Rouba Ali-Fehmi and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vidya PatilSimon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, United States.
Julie J RuterbuschDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Wei ChenDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Julie L BoernerDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Eman AbdulfatahDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Baraa AloshDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Visakha PardeshiDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Asra N ShaikDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, United States.
Sudeshna BandyopadhyayDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, United States.
Rouba Ali-Fehmi *Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United States.
Michele L Cote *Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United States.

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
CCR NIH HHS HHSN261201300011CNCI NIH HHS P30 CA022453
6 · The paper itself

Abstract

The risk of developing subsequent breast cancer is higher in women diagnosed with benign breast disease (BBD) but these studies were primarily performed in non-Hispanic white populations. Still, these estimates have been used to inform breast cancer risk models that are being used clinically across all racial and ethnic groups. Given the high breast cancer mortality rates among African American (AA) women, it is critical to study BBD in this population, to ensure the risk models that include this information perform adequately. This study utilized data from AA women who underwent benign breast biopsies at a hospital served by the University Pathology Group in Detroit, Michigan, from 1998 to 2010. Patients were followed for subsequent breast cancers through the population-based Metropolitan Detroit Cancer Surveillance System (MDCSS). BBD lesion scores were assigned to represent the severity or extent of benign breast lesions, with higher scores indicating a greater number of distinct lesion types. Of 3,461 eligible AA women with BBD in the cohort, 6.88% (n=238) subsequently developed breast cancer. Examined individually, six of the eleven lesions (apocrine metaplasia, ductal hyperplasia, lobular hyperplasia, intraductal papilloma, sclerosing adenosis, columnar alterations and radial scars) were significantly associated with increased risk of breast cancer after adjustment for age and year of biopsy and were further considered in multiple lesion models. For every different type of benign breast lesion, subsequent risk of breast cancer increased by 25% (RR=1.25, 95% CI: 1.10, 1.42) after adjustment for age at biopsy and proliferative versus non-proliferative disease. In summary, this study affirms the increased breast cancer risk in AA women with BBD, particularly in those with multiple lesions. These findings have implications for the management of breast cancer risk in millions of women affected by BBD, a high risk group that could benefit from personalized surveillance and risk reduction strategies.

Indexed as

African Americanbenign breast diseasebreast biopsybreast cancerhyperplasia

Identifiers

PMID38817898
PMCPMC11137188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.